首页 | 本学科首页   官方微博 | 高级检索  
     


An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
Authors:Osorio A,Pollán M,Pita G,Schmutzler R K,Versmold B,Engel C,Meindl A,Arnold N,Preisler-Adams S,Niederacher D,Hofmann W,Gadzicki D,Jakubowska A,Hamann U,Lubinski J,Toloczko-Grabarek A,Cybulski C,Debniak T,Llort G,Yannoukakos D,Díez O,Peissel B,Peterlongo P,Radice P,Heikkinen T,Nevanlinna H,Mai P L,Loud J T,McGuffog L,Antoniou A C,Benitez J  CIMBA
Affiliation:Human Cancer Genetics Programme, Human Genetics Group, Spanish National Cancer Centre, Madrid, Spain. aosorio@cnio.es
Abstract:The close functional relationship between p53 and the breast cancer susceptibility genes BRCA1 and BRCA2 has promoted the investigation of various polymorphisms in the p53 gene as possible risk modifiers in BRCA1/2 mutation carriers. Specifically, two polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon 72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the Spanish population. In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
Keywords:BRCA1   BRCA2   p53   breast cancer
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号